2008;29: 1495 503. 583. AstraZeneca. Brilinta REMS document. NDA 22-433. Reference ID: 2976456. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM264004. pdf. [Package insert]. Accessed September 9, 2011. 584. Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial com- paring infarct artery stenting plus abciximab with stenting alone. Circu- lation. 2004;109:1704 6. 585. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angio-graphic reste- nosis rate after the placement of coronary stents following acute myo- cardial infarction. J Am Coll Cardiol. 2000;35:915 21. 586. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957 66. 587. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glyco-protein IIb/IIIa inhibition with coronary stenting for acute myocar-dial infarction. N Engl J Med. 2001;344:1895 903. 588. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarc- tion: a meta-analysis of randomized trials. JAMA. 2005;293:1759 65. 589. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percu- taneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009;119:1933 40. 590. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J. 2009;30:2705 13. 591. Bellandi F, Maioli M, Gallopin M, et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. 